Journal Watch · Frontiers in Immunology · 2026

Case Report: Complete remission of Guillain-Barré syndrome in neuropsychiatric lupus with telitacicept.

This first report of telitacicept use in NPSLE-GBS demonstrates that dual BLyS/APRIL inhibition can achieve complete remission in refractory cases, offering a promising therapeutic approach that warrants further investigation in controlled trials.

Bao Y, Zhang W, Liu X, Gai NFrontiers in Immunology3 min readPharma relevance 75/100

DOI: 10.3389/fimmu.2026.1726901PMID: 41659868Study type: case report / series

TL;DR

This first report of telitacicept use in NPSLE-GBS demonstrates that dual BLyS/APRIL inhibition can achieve complete remission in refractory cases, offering a promising therapeutic approach that warrants further investigation in controlled trials.

Key findings

  • Corticosteroids were successfully tapered to 4mg daily without disease flare.
  • This first report of telitacicept use in NPSLE-GBS demonstrates that dual BLyS/APRIL inhibition can achieve complete remission in refractory cases, offering a promising therapeutic approach that warrants further investigation in controlled trials.

Numbers at a glance (from the abstract)

61.6%82.8%

Every figure above is taken verbatim from the abstract below. Check the full text for denominators, confidence intervals and subgroup detail.

What they did

Cerebrospinal fluid analysis showed cytoalbuminologic dissociation (protein 1314 mg/L, cells 1×10<sup>6</sup>/L), and nerve conduction studies confirmed acute inflammatory demyelinating polyradiculoneuropathy. Following inadequate response to intravenous immunoglobulin monotherapy, combination treatment was initiated with methylprednisolone (40mg daily), cyclophosphamide (0.6g biweekly), hydroxychloroquine, and telitacicept (160mg weekly), a novel dual inhibitor of B lymphocyte stimulator and a proliferation-inducing ligand that simultaneously targets B cells and plasma cells. At six-month follow-up, the patient achieved complete neurological recovery with significant laboratory improvements: immunoglobulin G decreased 61.6% to 9.34 g/L, anti-double-stranded DNA antibodies decreased 82.8% to 22 IU/ml, erythrocyte sedimentation rate normalized from 63 to 8 mm/h, and complement levels recovered.

Full abstract (original)

Background: Neuropsychiatric systemic lupus erythematosus (NPSLE) manifesting as Guillain-Barré syndrome (GBS) is exceptionally rare, with only 28 documented cases in medical literature, and current biological therapies show limited efficacy. We report a 34-year-old woman who presented with progressive quadriparesis, bilateral ptosis, and facial palsy developing over one month. Laboratory investigations revealed marked B-cell dysregulation with elevated immunoglobulin G (24.30 g/L, normal 7-16), positive antinuclear antibodies (1:320), anti-double-stranded DNA antibodies (128 IU/ml, normal <20), anti-ribosomal P antibodies (450 AU/ml, normal <20), and hypocomplementemia (C3 1.10 g/L, C4 0.28 g/L).

What they did: Cerebrospinal fluid analysis showed cytoalbuminologic dissociation (protein 1314 mg/L, cells 1×10<sup>6</sup>/L), and nerve conduction studies confirmed acute inflammatory demyelinating polyradiculoneuropathy. Following inadequate response to intravenous immunoglobulin monotherapy, combination treatment was initiated with methylprednisolone (40mg daily), cyclophosphamide (0.6g biweekly), hydroxychloroquine, and telitacicept (160mg weekly), a novel dual inhibitor of B lymphocyte stimulator and a proliferation-inducing ligand that simultaneously targets B cells and plasma cells. At six-month follow-up, the patient achieved complete neurological recovery with significant laboratory improvements: immunoglobulin G decreased 61.6% to 9.34 g/L, anti-double-stranded DNA antibodies decreased 82.8% to 22 IU/ml, erythrocyte sedimentation rate normalized from 63 to 8 mm/h, and complement levels recovered.

Results & conclusions: Corticosteroids were successfully tapered to 4mg daily without disease flare. This first report of telitacicept use in NPSLE-GBS demonstrates that dual BLyS/APRIL inhibition can achieve complete remission in refractory cases, offering a promising therapeutic approach that warrants further investigation in controlled trials.

Abstract © the authors / Frontiers in Immunology (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.3389/fimmu.2026.1726901 · PubMed 41659868.

Why it matters for pharma & biotech

  • Directly relevant to teams in small-molecule drug discovery — the abstract reports new data in that space, so competitive and pipeline teams should read the full text.
  • As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
  • For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.

Modalities & themes detected: small-molecule drug discovery

Limitations & what to check in the full text

  • This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.

Frequently asked questions

What did this Frontiers in Immunology study find?

This first report of telitacicept use in NPSLE-GBS demonstrates that dual BLyS/APRIL inhibition can achieve complete remission in refractory cases, offering a promising therapeutic approach that warrants further investigation in controlled trials.

What type of study is this?

It is a case report / series, published in Frontiers in Immunology in 2026. Cerebrospinal fluid analysis showed cytoalbuminologic dissociation (protein 1314 mg/L, cells 1×10<sup>6</sup>/L), and nerve conduction studies confirmed acute inflammatory demyelinating polyradiculoneuropathy.

Where can I read the original paper?

The original is at the publisher via DOI 10.3389/fimmu.2026.1726901. PubMed ID: 41659868. BioStudioAI reproduces the abstract for discussion and links to the source.

How to cite the original: Bao Y, Zhang W, Liu X, Gai N. Case Report: Complete remission of Guillain-Barré syndrome in neuropsychiatric lupus with telitacicept.. Frontiers in Immunology (2026). DOI: 10.3389/fimmu.2026.1726901.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/case-report-complete-remission-of-guillain-barre-syndrome-in-neuropsychi-726901/

Reading papers is step one. Analysing the data is the work.

BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.

Open BioStudioAI More guides